CEP-1347 | KT-7515 | CAS#156177-65-0 | JNK/SAPK inhibitor

CEP-1347
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326995

CAS#: 156177-65-0

Description: CEP-1347, also known as KT-7515, 3,9-Bis(etsm)-K-252a, is a potent and selective JNK/SAPK inhibitor potentially for the treatment of neurodegenerative diseases. CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. CEP-1347 increases ChAT activity in culture and promotes cholinergic neurone survival following fimbria-fornix lesion. CEP-1347 inhibits caerulein-induced rat pancreatic JNK activation and ameliorates caerulein pancreatitis.

Chemical Structure

CEP-1347

CAS# 156177-65-0

Instruction

Theoretical Analysis

MedKoo Cat#: 326995
Name: CEP-1347
CAS#: 156177-65-0
Chemical Formula: C33H33N3O5S2
Exact Mass: 615.19
Molecular Weight: 615.763
Elemental Analysis: C, 64.37; H, 5.40; N, 6.82; O, 12.99; S, 10.41

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 450
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: CEP-1347; CEP 1347; CEP1347; KT-7515; KT 7515; KT7515.3,9-Bis((ethylthio)methyl)-K-252a; 3,9-Bis(etsm)-K-252a

IUPAC/Chemical Name: methyl (5S,6R,8R)-2,11-bis((ethylthio)methyl)-6-hydroxy-5-methyl-13-oxo-5,6,7,8,14,15-hexahydro-13H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacene-6-carboxylate

InChi Key: SCMLRESZJCKCTC-KMYQRJGFSA-N

InChi Code: InChI=1S/C33H33N3O5S2/c1-5-42-15-17-7-9-22-19(11-17)26-27-21(14-34-30(27)37)25-20-12-18(16-43-6-2)8-10-23(20)36-29(25)28(26)35(22)24-13-33(39,31(38)40-4)32(36,3)41-24/h7-12,24,39H,5-6,13-16H2,1-4H3,(H,34,37)/t24-,32+,33+/m1/s1

SMILES Code: O=C([C@]1(O)[C@@](O2)(C)N3C4=CC=C(CSCC)C=C4C5=C3C6=C(C7=CC(CSCC)=CC=C7N6[C@@]2([H])C1)C8=C5CNC8=O)OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Certificate of Analysis:

View CoA: current batch, Lot#T20O06R22

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 615.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Ma Q, Gelbard HA, Maggirwar SB, Dewhurst S, Gendelman HE, Peterson DR, DiFrancesco R, Hochreiter JS, Morse GD, Schifitto G. Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. J Neurovirol. 2013 Jun;19(3):254-60. doi: 10.1007/s13365-013-0172-z. Epub 2013 Jun 5. PubMed PMID: 23737347; PubMed Central PMCID: PMC3760277.

2: Sweeney ZK, Lewcock JW. ACS chemical neuroscience spotlight on CEP-1347. ACS Chem Neurosci. 2011 Jan 19;2(1):3-4. doi: 10.1021/cn1000793. Epub 2010 Sep 3. Review. PubMed PMID: 22778853; PubMed Central PMCID: PMC3369704.

3: Eggert D, Dash PK, Gorantla S, Dou H, Schifitto G, Maggirwar SB, Dewhurst S, Poluektova L, Gelbard HA, Gendelman HE. Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol. 2010 Jan 15;184(2):746-56. doi: 10.4049/jimmunol.0902962. Epub 2009 Dec 4. PubMed PMID: 19966207; PubMed Central PMCID: PMC2805820.

4: Wang LH, Johnson EM Jr. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2008 Aug 5;71(6):462; author reply 462-3. doi: 10.1212/01.wnl.0000324506.93877.5e. PubMed PMID: 18678833.

5: Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, Conforti P, Ramos C, Roarke M, Kathuria S, Cattaneo E, Marsh JL, Thompson LM. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci. 2008 Sep;39(1):8-20. doi: 10.1016/j.mcn.2008.04.007. Epub 2008 Apr 24. PubMed PMID: 18602275.

6: Conforti P, Ramos C, Apostol BL, Simmons DA, Nguyen HP, Riess O, Thompson LM, Zuccato C, Cattaneo E. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol Cell Neurosci. 2008 Sep;39(1):1-7. doi: 10.1016/j.mcn.2008.04.012. Epub 2008 May 10. PubMed PMID: 18571429.

7: Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007 Oct 9;69(15):1480-90. Epub 2007 Sep 19. PubMed PMID: 17881719.

8: Lund S, Porzgen P, Mortensen AL, Hasseldam H, Bozyczko-Coyne D, Morath S, Hartung T, Bianchi M, Ghezzi P, Bsibsi M, Dijkstra S, Leist M. Inhibition of microglial inflammation by the MLK inhibitor CEP-1347. J Neurochem. 2005 Mar;92(6):1439-51. PubMed PMID: 15748162.

9: Falsig J, Pörzgen P, Lotharius J, Leist M. Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347. J Immunol. 2004 Aug 15;173(4):2762-70. PubMed PMID: 15294995.

10: Parkinson Study Group. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology. 2004 Jan 27;62(2):330-2. PubMed PMID: 14745084.

11: Boll JB, Geist MA, Kaminski Schierle GS, Petersen K, Leist M, Vaudano E. Improvement of embryonic dopaminergic neurone survival in culture and after grafting into the striatum of hemiparkinsonian rats by CEP-1347. J Neurochem. 2004 Feb;88(3):698-707. PubMed PMID: 14720219.

12: Bilsland JG, Harper SJ. CEP-1347 promotes survival of NGF responsive neurones in primary DRG explants. Neuroreport. 2003 May 23;14(7):995-9. PubMed PMID: 12802190.

13: Mucke HA. CEP-1347 (Cephalon). IDrugs. 2003 Apr;6(4):377-83. Review. PubMed PMID: 12789610.

14: Saporito MS, Hudkins RL, Maroney AC. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog Med Chem. 2002;40:23-62. Review. PubMed PMID: 12516522.

15: Harris CA, Deshmukh M, Tsui-Pierchala B, Maroney AC, Johnson EM Jr. Inhibition of the c-Jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. J Neurosci. 2002 Jan 1;22(1):103-13. PubMed PMID: 11756493.

16: Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, Scott RW. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J Neurochem. 2001 May;77(3):849-63. PubMed PMID: 11331414.

17: Maroney AC, Finn JP, Connors TJ, Durkin JT, Angeles T, Gessner G, Xu Z, Meyer SL, Savage MJ, Greene LA, Scott RW, Vaught JL. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem. 2001 Jul 6;276(27):25302-8. Epub 2001 Apr 26. PubMed PMID: 11325962.

18: O'Ferrall EK, Robertson J, Mushynski WE. Inhibition of aberrant and constitutive phosphorylation of the high-molecular-mass neurofilament subunit by CEP-1347 (KT7515), an inhibitor of the stress-activated protein kinase signaling pathway. J Neurochem. 2000 Dec;75(6):2358-67. PubMed PMID: 11080187.

19: Harper SJ, Saporito MS, Hewson L, Young L, Smith D, Rigby M, Jackson P, Curtis N, Swain C, Hefti F, Vaught JL, Sirinathsinghji D. CEP-1347 increases ChAT activity in culture and promotes cholinergic neurone survival following fimbria-fornix lesion. Neuroreport. 2000 Jul 14;11(10):2271-6. PubMed PMID: 10923684.

20: Wagner AC, Mazzucchelli L, Miller M, Camoratto AM, Göke B. CEP-1347 inhibits caerulein-induced rat pancreatic JNK activation and ameliorates caerulein pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2000 Jan;278(1):G165-72. PubMed PMID: 10644575.

Your view history

CEP-1347 featured